Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Molecular Residual Disease Detection Via Cancer Personalized Profiling By Deep Sequencing in Patients with PTCL Undergoing Autologous Stem Cell Transplantation

Chandan Sanghera, Josie Ford, Ruwan Gunaratne, Kusha Chopra, Anna B Rider, Aliyah R. Sohani, Sean M McCabe, Ronald A Nemec, Yi-Bin Chen, Steven McAfee, Ephraim Hochberg, Jeffrey A. Barnes, Caroline MacVicar, Eric D. Jacobsen, Mwanasha H. Merrill, Michael S. Khodadoust, David Kurtz, Salvia Jain

Blood (2024) 144 (Supplement 1): 6202.

https://doi.org/10.1182/blood-2024-206116

Published: 2024

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood (2024) 144 (Supplement 1): 466.

https://doi.org/10.1182/blood-2024-194796

Published: 2024

Journal Articles

Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas

Blood (2024) 144 (Supplement 1): 454.

https://doi.org/10.1182/blood-2024-206518

Published: 2024

Journal Articles

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Jasmine Zain, Swaminathan P Iyer, Enrica Marchi, Mitul Gandhi, Youn H. Kim, Michael S. Khodadoust, Jonathan E. Brammer, Christina Poh, Pierluigi Porcu, Kimberley Dilley, Matthias Will, Andrea Kantor, Cathrine Leonowens, Nenad Tomasevic, H. Miles Prince, Steven Horwitz

Blood (2024) 144 (Supplement 1): 980.

https://doi.org/10.1182/blood-2024-206053

Published: 2024

Journal Articles

Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival

Ruwan Gunaratne, Crystal Zhou, Jesse W. Tai, Sky Kim, Kailee Tanaka, Sanjeeth Rajaram, Mia Carleton, Raymond Yin, Matthew Alkaitis, Matthew Schwede, Brian J. Sworder, Michael S. Khodadoust, Ravi Majeti, David Kurtz, Tian Y Zhang

Blood (2024) 144 (Supplement 1): 2955.

https://doi.org/10.1182/blood-2024-201701

Published: 2024

Journal Articles

Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Leyla Bojanini, Melba Herrera, Shufeng Li, Tarek Bandali, Nicole Y. Xu, Abdullah A. Ahmed, Michael S. Khodadoust, Youn H. Kim

Blood (2024) 144 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2024-198783

Published: 2024

Journal Articles

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2024-200587

Published: 2024

Journal Articles

Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4846.

https://doi.org/10.1182/blood-2024-207885

Published: 2024

Journal Articles

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Alexa C Kwang, George E Duran, Sebastian Fernandez-Pol, Safa Najidh, Shufeng Li, Armando N Bastidas Torres, Erica B Wang, Melba Herrera, Tarek I Bandali, David M Kurtz, Youn H Kim, Michael S Khodadoust

Blood blood.2024024817.

https://doi.org/10.1182/blood.2024024817

Published: 2024

Includes: Supplemental data

Journal Articles

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Ruwan Gunaratne, Crystal Zhou, Jesse W. Tai, Matthew Schwede, Kailee Tanaka, Matthew Alkaitis, Raymond Yin, Brian J. Sworder, Gabriel Mannis, Ravindra Majeti, Michael S. Khodadoust, David M. Kurtz, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2023-181459

Published: 2023

Journal Articles

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Blood (2023) 142 (Supplement 1): 185.

https://doi.org/10.1182/blood-2023-173806

Published: 2023

Journal Articles

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2023-190775

Published: 2023

Journal Articles

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Blood (2023) 142 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2023-184898

Published: 2023

Journal Articles

An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring

Takeshi Sugio, Navika Shukla, Michael S Khodadoust, Monica Nesselbush, Koji Kato, Stefan K. Alig, Jan Boegeholz, Joseph Schroers-Martin, Mohammad Shahrokh Esfahani, Jurik A. Mutter, Andrea Garofalo, Soyeong Jun, Mark P. Hamilton, Cédric Rossi, Mari Olsen, Chih Long Liu, Koichi Akashi, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2023-180492

Published: 2023

Journal Articles

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Michael S. Khodadoust, Eric Mou, Youn H. Kim

Blood (2023) 141 (7): 695–703.

https://doi.org/10.1182/blood.2020008241

Published: 2023

Journal Articles

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1301–1303.

https://doi.org/10.1182/blood-2022-165545

Published: 2022

Journal Articles

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Martine Bagot, Youn H. Kim, Pablo L. Ortiz-Romero, Pier Luigi Zinzani, Neha Mehta-Shah, Olivier Dereure, Marie Beylot-Barry, Stéphane Dalle, Eric D Jacobsen, Auris Huen, Andrea Combalia, Maxime Battistella, Alejandro A. Gru, Hélène Moins-Teisserenc, Michael S. Khodadoust, Julien Viotti, Christine Paiva, Marianna Muller, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 3760–3761.

https://doi.org/10.1182/blood-2022-160239

Published: 2022

Journal Articles

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas

Eric Mou, Sebastian Fernandez-Pol, Shufeng Li, Youn H. Kim, Michael S. Khodadoust

Blood (2022) 140 (Supplement 1): 6552–6553.

https://doi.org/10.1182/blood-2022-158610

Published: 2022

Journal Articles

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

Tanaya Shree, Sarah Haebe, Debra K. Czerwinski, Erik Eckhert, Grady Day, Anuja Sathe, Susan M. Grimes, Matthew J Frank, Lauren S. Maeda, Ash A. Alizadeh, Ranjana H. Advani, Richard Hoppe, Steven R. Long, Brock Martin, Michael G. Ozawa, Michael S. Khodadoust, Hanlee P. Ji, Ronald Levy

Blood (2022) 140 (Supplement 1): 6450–6451.

https://doi.org/10.1182/blood-2022-167469

Published: 2022

Journal Articles

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Hitomi Hosoya, Mia Carleton, Kailee L Tanaka, Brian Sworder, Vanna Hovanky, George E Duran, Tian Y. Zhang, Michael S. Khodadoust, David B. Miklos, Sally Arai, David Iberri, Michaela Liedtke, Surbhi Sidana, David M. Kurtz

Blood (2022) 140 (Supplement 1): 1546–1548.

https://doi.org/10.1182/blood-2022-160370

Published: 2022

NARROW

Molecular Residual Disease Detection Via Cancer Personalized Profiling By Deep Sequencing in Patients with PTCL Undergoing Autologous Stem Cell Transplantation

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival

Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only